FDA approves Dupixent for allergic fungal rhinosinusitis
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.
Feb 26, 2026
0
6
